Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, Scheid C, Hose D, Seckinger A, Luntz S, Besemer B, Munder M, Brossart P, Glass B, Lindemann HW, Weisel K, Hanoun C, Schnitzler P, Klemm S, Goldschmidt H, Raab M, Elmaagacli A. Salwender H, et al. Among authors: scheid c. Hematology. 2024 Dec;29(1):2320006. doi: 10.1080/16078454.2024.2320006. Epub 2024 Feb 26. Hematology. 2024. PMID: 38407192 Clinical Trial.
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C. Chemnitz JM, et al. Among authors: scheid c. Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17. Ann Hematol. 2012. PMID: 21584670
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Neben K, et al. Among authors: scheid c. Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8. Blood. 2012. PMID: 22160383 Free article. Clinical Trial.
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Sonneveld P, et al. Among authors: scheid c. J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. J Clin Oncol. 2012. PMID: 22802322 Free article. Clinical Trial.
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.
Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group. Auel B, et al. Among authors: scheid c. Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18. Indian J Hematol Blood Transfus. 2012. PMID: 23730012 Free PMC article.
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM. Scheid C, et al. Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30. Haematologica. 2014. PMID: 23996482 Free PMC article. Clinical Trial.
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.
Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B. Straka C, et al. Among authors: scheid c. Leuk Lymphoma. 2015 Feb;56(2):368-76. doi: 10.3109/10428194.2014.919631. Epub 2014 May 27. Leuk Lymphoma. 2015. PMID: 24794810
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H. Merz M, et al. Among authors: scheid c. Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3. Haematologica. 2015. PMID: 25840597 Free PMC article. Clinical Trial.
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK, Benner A, Bertsch U, Brossart P, Hänel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H. Mai EK, et al. Among authors: scheid c. Br J Haematol. 2016 Jun;173(5):731-41. doi: 10.1111/bjh.13994. Epub 2016 Mar 17. Br J Haematol. 2016. PMID: 26990892 Free article. Clinical Trial.
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H. Baertsch MA, et al. Among authors: scheid c. BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2. BMC Cancer. 2016. PMID: 27114074 Free PMC article. Clinical Trial.
325 results